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ABSTRACT
Introduction: Smoking may reduce the efficacy
of inhaled corticosteroids (ICS) in patients with
chronic obstructive pulmonary disease (COPD),
but its impact on bronchodilator efficacy is
unclear. This analysis of the EMAX trial
explored efficacy and safety of dual- versus
mono-bronchodilator therapy in current or
former smokers with COPD.
Methods: The 24-week EMAX trial evaluated
lung function, symptoms, health status,
exacerbations, clinically important deteriora-
tion, and safety with umeclidinium/vilanterol,
umeclidinium, and salmeterol in symptomatic
patients at low exacerbation risk who were not
receiving ICS. Current and former smoker sub-
groups were defined by smoking status at
screening.
Results: The analysis included 1203 (50%)
current smokers and 1221 (50%) former smok-
ers. Both subgroups demonstrated greater
improvements from baseline in trough FEV1 at
week 24 (primary endpoint) with umecli-
dinium/vilanterol versus umeclidinium (least
squares [LS] mean difference, mL [95% CI];
current: 84 [50, 117]; former: 49 [18, 80]) and
salmeterol (current: 165 [132, 198]; former: 117
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[86, 148]) and larger reductions in rescue med-
ication inhalations/day over 24 weeks versus
umeclidinium (LS mean difference [95% CI];
current: - 0.42 [- 0.63, - 0.20]; former: - 0.25
- 0.44, - 0.05]) and salmeterol (current: - 0.28
[- 0.49, - 0.06]; former: - 0.29 [- 0.49,
- 0.09]). Umeclidinium/vilanterol increased
the odds (odds ratio [95% CI]) of clinically sig-
nificant improvement at week 24 in Transition
Dyspnea Index versus umeclidinium (current:
1.54 [1.16, 2.06]; former: 1.32 [0.99, 1.75]) and
salmeterol (current: 1.37 (1.03, 1.82]; former:
1.60 [1.20, 2.13]) and Evaluating Respiratory
Symptoms–COPD versus umeclidinium (cur-
rent: 1.54 [1.13, 2.09]; former: 1.50 [1.11, 2.04])
and salmeterol (current: 1.53 [1.13, 2.08]; for-
mer: 1.53 [1.12, 2.08]). All treatments were well
tolerated in both subgroups.
Conclusions: In current and former smokers,
umeclidinium/vilanterol provided greater
improvements in lung function and symptoms
versus umeclidinium and salmeterol, support-
ing consideration of dual-bronchodilator ther-
apy in symptomatic patients with COPD
regardless of their smoking status.
PLAIN LANGUAGE SUMMARY
Patients with chronic obstructive pulmonary
disease (COPD) often require daily medication
to control their COPD. Many patients with
COPD are smokers, and smoking is one of the
most common causes of COPD. This means that
it is important to find out whether COPD
medications are effective in both smokers and
nonsmokers. We analyzed data from a clinical
trial (EMAX) that investigated the use of a
combination of two bronchodilators, which are
inhaled medications that help to open the air-
ways. We compared umeclidinium/vilanterol, a
dual-bronchodilator combination, with a single
bronchodilator (either umeclidinium or salme-
terol) over 6 months. We found that both cur-
rent and former smokers who were treated with
umeclidinium/vilanterol had larger improve-
ments in lung function than those receiving
umeclidinium or salmeterol. Current or former
smokers who were treated with umeclidinium/
vilanterol used their reliever inhaler less than
those treated with umeclidinium or salmeterol.
Patients treated with umeclidinium/vilanterol
were generally less likely to experience disease
worsening compared with umeclidinium or
salmeterol if they were former smokers, or
compared with salmeterol if they were current
smokers. Our findings suggest that umecli-
dinium/vilanterol may be more effective than a
single bronchodilator for daily treatment of
patients with COPD who are current or former
smokers. Physicians should consider prescribing
a combination of two bronchodilators to
patients who have symptoms, whether or not
they currently smoke, as well as encouraging
smoking cessation for all patients.
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Why carry out this study?
Clinical trials have demonstrated
significantly greater improvements in
lung function, symptoms, and health-
related quality of life with long-acting
muscarinic antagonist/long-acting b2-
agonist (LAMA/LABA) dual therapies
compared with LAMA or LABA
monotherapies; however, few studies have
explored the efficacy of these treatments
in current and former smokers with
chronic obstructive pulmonary disease
(COPD).
This prespecified analysis of the
randomized, double-blind EMAX trial
explored the efficacy and safety of
umeclidinium/vilanterol (UMEC/VI)
compared with UMEC or salmeterol (SAL)
in current and former smokers.
What was learned during this study?
Improvements in lung function and
reductions in rescue medication use were
seen in both current and former smokers
receiving UMEC/VI compared with those
treated with UMEC or SAL.
These findings suggest that dual-
bronchodilator therapy may be an
appropriate treatment option for patients
with symptomatic COPD irrespective of
their smoking status.
INTRODUCTION
In patients with chronic obstructive pulmonary
disease (COPD), poorly controlled symptoms
are associated with worse health-related quality
of life, increased risk of COPD exacerbations,
and a poor disease prognosis [1–3]. Smoking is
one of the most prominent risk factors for
COPD, and the prevalence of COPD is higher in
current and former smokers than in nonsmok-
ers [4]. Among patients with COPD, current
smokers have a greater rate of decline in lung
function than former smokers [5, 6], and
smoking also has an impact on COPD symp-
toms and health status [7, 8]. Smoking cessation
can reduce long-term mortality risk [9] and is
therefore an important element of COPD man-
agement, along with pharmacological mainte-
nance therapy for many patients [4, 10].
However, it remains unclear how the efficacy of
maintenance treatment for COPD is affected by
patients’ smoking behavior.
Long-acting bronchodilators are recom-
mended for most patients requiring mainte-
nance therapy for COPD [4, 10]. Many patients
remain symptomatic during treatment with one
long-acting bronchodilator [11], suggesting a
need for additional therapy. Analyses of clinical
trial data have demonstrated greater improve-
ments in lung function, symptoms, and health
status with long-acting muscarinic antago-
nist/long-acting b2-agonist (LAMA/LABA) dual
therapy compared with LAMA or LABA
monotherapy [12–15]. The efficacy of inhaled
corticosteroid (ICS) treatment in patients with
COPD appears to be impaired by smoking, but
the effect of smoking on the efficacy of bron-
chodilators is less well understood. A post hoc
analysis of the 12-month SUMMIT trial showed
blunted improvement in lung function with ICS
and ICS/LABA versus placebo, as well as a
smaller reduction in exacerbation rates with
ICS/LABA versus placebo, among current
smokers compared with former smokers [16]. A
systematic review of seven clinical trials (in-
cluding SUMMIT) also found that current
smokers gained less benefit from ICS-containing
therapy than former smokers [17]. In contrast,
the SUMMIT analysis showed similar benefits of
the LABA vilanterol versus placebo between
current and former smokers [16]. The LAMAs
tiotropium and glycopyrronium have also
demonstrated improvements in lung function
and health-related quality of life compared with
placebo in both current and former smokers
[18, 19]. Similarly, in a post hoc analysis of the
FLIGHT studies, improvements in lung func-
tion, symptoms, and health status observed
with the LAMA/LABA indacaterol/
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glycopyrronium compared with its constituent
monotherapies and placebo after 12 weeks of
treatment were similar between current and
former smokers [20]. Taken together this evi-
dence suggests that, in contrast with ICS-con-
taining therapy, the efficacy of bronchodilator
therapy is less affected by patients’ smoking
status.
The aim of this prespecified analysis of the
EMAX trial was to evaluate the efficacy and
safety of umeclidinium/vilanterol in current
and former smokers with COPD. We hypothe-
sized that both current smokers and former
smokers would achieve greater improvements
in lung function, symptoms, and health status
with umeclidinium/vilanterol (UMEC/VI) com-
pared with UMEC and salmeterol (SAL). In
addition, we explored whether the magnitude
of improvements from baseline with UMEC/VI,
UMEC, or SAL was similar in current and former
smokers.
METHODS
Study Design and Ethical Approval
EMAX was a multicenter, double-blind, double-
dummy, three-arm parallel-group trial, in
which patients were randomized 1:1:1 to
24 weeks of once-daily UMEC/VI (62.5/25 lg)
via the ELLIPTA inhaler, once-daily UMEC
(62.5 lg) via ELLIPTA, or twice-daily SAL (50 lg)
via the DISKUS inhaler. The trial began in June
2017 and was completed in June 2018. Full
details of the trial methodology have been
published previously [21].
The EMAX trial was conducted in accordance
with the principles of the 1964 Declaration of
Helsinki and its later amendments, and received
appropriate ethical approval (Supplementary
Table S1). Patients provided written informed
consent at the pre-screening or screening visit.
Patients
Eligible patients were at least 40 years of age and
were current/former smokers with a COPD
diagnosis, pre- and post-albuterol forced
expiratory volume in 1 s/forced vital capacity
(FEV1/FVC) ratio\0.7, post-albuterol FEV1 of at
least 30% to at most 80% predicted (Global
Initiative for Chronic Obstructive Lung Disease
[GOLD] grade 2/3), COPD Assessment Test
(CAT) score C 10, and at most one moderate
and no severe exacerbations in the previous
year. Prior to screening and during the 4-week
run-in period, treatment with at most one
maintenance bronchodilator monotherapy
(LAMA or LABA) was permitted. Patients had no
ICS or ICS/LABA treatment for at least 6 weeks
prior to run-in, and no LAMA/LABA combina-
tion therapy for at least 2 weeks prior to run-in.
After the run-in period, patients received study
treatment for 24 weeks.
In this analysis, patients were categorized
into two subgroups based on their smoking
status at screening (current smoker or former
smoker). The EMAX trial did not include any
patients who had never smoked.
Endpoints
Outcomes evaluated in the EMAX trial included
spirometry, patient-reported outcomes (PROs),
exacerbations, clinically important deteriora-
tions (CID), and safety. For this analysis,
spirometry outcomes were change from base-
line in trough FEV1, FVC, and inspiratory
capacity (IC). PROs were self-administered
computerized Transition Dyspnea Index (SAC-
TDI) focal score, Evaluating Respiratory Symp-
toms–COPD (E-RS) total score, rescue medica-
tion use (inhalations/day and the proportion of
rescue-free days), global assessment of disease
severity (GADS), St George’s Respiratory Ques-
tionnaire (SGRQ) total score, and CAT total
score. Response rates were also evaluated for
SAC-TDI score (at least a 1-unit improvement
from baseline) [22], E-RS score (at least a 2-point
reduction from baseline) [23], SGRQ score (at
least a 4-point reduction from baseline) [24],
and CAT score (at least a 2-point reduction from
baseline) [25]. Risk of a first CID was assessed in
individual patients according to three compos-
ite definitions: 1. a first moderate or severe
exacerbation, and/or a trough FEV1 decrease
from baseline of at least 100 mL, and/or a
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deterioration in SGRQ (at least 4 units from
baseline); 2. as per the first definition with a
CAT deterioration (at least 2 units from base-
line) replacing SGRQ deterioration; 3. a first
moderate or severe exacerbation, and/or a
SGRQ deterioration, and/or a CAT deteriora-
tion, and/or a SAC-TDI deterioration (at least a
1-unit decrease from baseline). Safety outcomes
included the incidence of adverse events (AEs)
and serious AEs (SAEs).
Statistical Analysis
The EMAX trial was powered to detect differ-
ences in trough FEV1 and SAC-TDI at week 24 in
the intent-to-treat (ITT) population. The trial
was not powered to detect differences between
treatments in the smaller smoking status sub-
groups, so no formal statistical comparison was
performed between subgroups. Accordingly,
treatment differences with 95% confidence
intervals (CI) are reported without reference to
statistical significance between subgroups;
however, P values are shown in the figures and
tables.
Full details of the statistical analyses have
been reported previously [21]. Mixed model
repeated measures (MMRM) analyses were per-
formed for change from baseline in spirometry
outcomes and PROs, and least squares (LS)
mean and LS mean change from baseline are
reported with estimated treatment differences
and 95% CIs. Generalized linear mixed model
analyses were used to evaluate response rates,
and corresponding odds ratios (OR) are reported
with 95% CIs. A Cox proportional hazards
model was used to generate hazard ratios (HR)
and 95% CIs for time to first CID.
RESULTS
Study Population
The EMAX ITT population included 2425
patients, of whom 1203 (50%) were current
smokers (UMEC/VI: 394; UMEC: 396; SAL: 413)
and 1221 (50%) were former smokers (UMEC/
VI: 418; UMEC: 407; SAL: 396).
Table 1 shows baseline demographics and
clinical characteristics of current and former
smokers. On average, current smokers were
slightly younger than former smokers, and a
higher percentage were female. A greater pro-
portion of current smokers than former smokers
received no maintenance therapy in the 30 days
prior to screening. Current smokers had a
greater symptom burden as shown by higher
baseline E-RS, CAT, and SGRQ scores and rescue
medication use at baseline. A slightly smaller
proportion of current smokers than former
smokers experienced a moderate exacerbation
in the prior year. Within each subgroup, base-
line characteristics were well balanced between
treatment groups (Supplementary Table 2).
Lung Function Outcomes
Across all treatments and both subgroups, only
UMEC/VI in current smokers provided mean
improvements in trough FEV1 that consistently
exceeded the minimum clinically important
difference of 100 mL across all time points
(Fig. 1). At week 24, mean (95% CI) change
from baseline in trough FEV1 was higher with
UMEC/VI versus UMEC by 84 (50, 117) mL in
current smokers and 49 (18, 80) mL in former
smokers; the corresponding treatment differ-
ences for UMEC/VI versus SAL were 165 (132,
198) mL in current smokers and 117 (86, 148)
mL in former smokers (Table 2). Mean changes
from baseline in trough FVC and trough IC at
week 24 and all earlier time points were also
numerically greater with UMEC/VI than UMEC
and SAL in current and former smokers (Table 2;
Supplementary Fig. S1).
Symptom Severity and Health Status
Outcomes
In both current and former smokers, larger
mean SAC-TDI focal score and improvements
from baseline in E-RS total score were observed
with UMEC/VI compared with UMEC or SAL at
all time points (Table 2; Figs. 2, 3). There were
also greater odds of a clinically significant
improvement for both outcomes at week 24
with UMEC/VI compared with UMEC or SAL
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(percentage of responders; SAC-TDI: UMEC/VI,
49–51% vs UMEC and SAL, 39–42%; E-RS:
UMEC/VI, 35–37% vs UMEC and SAL, 26–29%;
Fig. 4). Patients receiving UMEC/VI demon-
strated larger reductions in mean rescue medi-
cation inhalations/day over 24 weeks versus
UMEC and SAL in both smoking subgroups
(Table 2; Figs. 5, 6). Improvements in the per-
centage of rescue-free days across all time points
were seen with UMEC/VI compared with UMEC
and SAL in current smokers, but this effect was
less clear in former smokers (Table 2; Figs. 5, 6).







Age, years, mean (SD) 64.6 (8.5) 61.7 (7.7) 67.5 (8.2)
Female, n (%) 988 (41) 561 (47) 427 (35)
Smoking pack-years, mean (SD) 48.4 (26.5) 48.0 (25.5) 48.8 (27.5)
No prior maintenance medication (from 30 days prior to
screening), n (%)
849 (35) 493 (41) 255 (21)
Patients with a moderate COPD exacerbation in prior
yeara, n (%)
393 (16) 164 (14) 228 (19)
Duration of COPD, years, mean (SD) 8.8 (6.9) 7.7 (6.3) 8.8 (6.8)
Post-salbutamol FEV1, mL, mean (SD) 1595 (511) 1647 (515) 1545 (502)
Post-salbutamol % predicted FEV1, mean (SD) 55.4 (12.7) 56.0 (12.5) 54.9 (12.9)
Post-salbutamol FEV1/FVC, mean (SD) 0.52 (0.10) 0.52 (0.10) 0.51 (0.10)
% reversibility to salbutamol, mean (SD) 10.5 (13.1) 10.8 (12.5) 10.1 (13.7)
GOLD spirometric gradeb, n (%)
2 (% predicted FEV1 50% to\ 80%) 1569 (65) 796 (66) 773 (63)
3 (% predicted FEV1 30% to\ 50%) 851 (35) 403 (33) 447 (37)
FEV1, mL, mean (SD) 1491 (517) 1545 (515) 1437 (514)
BDI score, mean (SD) 7.0 (1.9) 7.0 (2.0) 7.0 (1.8)
E-RS total score, mean (SD) 10.6 (5.7) 11.5 (5.8) 9.7 (5.6)
SGRQ score, mean (SD) 44.7 (16.2) 46.6 (16.8) 42.8 (15.2)
CAT score, mean (SD) 19.2 (6.1) 20.2 (6.4) 18.2 (5.7)
Rescue salbutamol, puffs/day, mean (SD) 2.2 (2.5) 2.5 (2.7) 1.9 (2.2)
BDI Baseline Dyspnoea Index, CAT COPD Assessment Test, COPD chronic obstructive pulmonary disease, E-RS Eval-
uating Respiratory Symptoms–COPD, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, GOLD Global
Initiative for Chronic Obstructive Lung Disease, ITT intent to treat, SAL salmeterol, SD standard deviation, SGRQ St
George’s Respiratory Questionnaire, UMEC umeclidinium
a Number of patients with exacerbations requiring oral or systemic corticosteroids and/or antibiotics (moderate) in
12 months prior to screening (patients with more than one moderate exacerbation or with a severe exacerbation [requiring
hospitalization] were excluded)
b An additional 4 (\ 1%) current smokers with GOLD grade 1 were randomized (UMEC n = 3; SAL n = 1)
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Change from baseline in mean SGRQ and
CAT scores across all time points were not
consistently greater with UMEC/VI versus
UMEC and SAL in current or former smokers
(Supplementary Fig. S2). The odds of a clinically
significant improvement in SGRQ score were
numerically greater with UMEC/VI versus
UMEC and SAL in both current smokers (per-
centage of responders; UMEC/VI: 45% vs
34–42%) and former smokers (percentage of
responders: 45% vs 38–40%) (Fig. 4). Similarly,
CAT responder rates were numerically higher
for UMEC/VI versus UMEC and SAL in current
smokers (percentage of responders; UMEC/VI:
52% vs 46–48%) and former smokers (percent-
age of responders; 58% vs 48–55%; Fig. 4).
Fig. 1 Change from baseline in trough FEV1 at weeks 4,
12, and 24 in A current smokers and B former smokers. CI
confidence interval, FEV1 forced expiratory volume in 1 s,
LS least squares, MCID minimum clinically important











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Exacerbations and Disease Stability
Outcomes
The risk of a first moderate/severe exacerbation
(HR [95% CI]) with UMEC/VI versus UMEC was
similar in current smokers (0.98 [0.65, 1.49]),
but reduced in former smokers (0.70 [0.50,
1.00]). Compared with SAL, UMEC/VI signifi-
cantly reduced the risk of a first moderate/sev-
ere exacerbation in both current (0.68 [0.46,
0.99]) and former smokers (0.60 [0.43, 0.85]).
In current smokers, the risk of a first CID was
reduced with UMEC/VI versus UMEC for one of
Fig. 2 A SAC-TDI focal score and B change from
baseline in E-RS total score across all time points in
current smokers. CI confidence interval, E-RS Evaluating
Respiratory Symptoms–COPD, LS least squares, MCID
minimum clinically important difference, SAC-TDI self-
administered computerized Transition Dyspnea Index,
SAL salmeterol, SGRQ St George’s Respiratory Question-
naire, UMEC umeclidinium, VI vilanterol
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three CID definitions, and versus SAL for all
three definitions, while in former smokers,
UMEC/VI reduced CID risk versus UMEC and
SAL for all three definitions (Fig. 7).
Effect of Smoking Status on Mean
Improvements from Baseline
For four clinical outcomes of interest (trough
FEV1, SAC-TDI, rescue medication
inhalations/day, and SGRQ score), LS mean
improvements in all treatment arms at week 24
were numerically larger in current smokers than
former smokers, with the exception of SGRQ
score in patients receiving SAL (Figs. 1, 2, 3, 5, 6,
S2A). For trough FEV1 in patients receiving
UMEC/VI (Fig. 1), and for rescue medication
inhalations/day in all treatment groups
(Figs. 5a, 6a), there was no overlap in the 95%
CIs between the subgroups, suggesting that
Fig. 3 A SAC-TDI focal score and B change from
baseline in E-RS total score across all time points in former
smokers. CI confidence interval, E-RS Evaluating Respira-
tory Symptoms–COPD, LS least squares, MCID
minimum clinically important difference, SAC-TDI self-
administered computerized Transition Dyspnea Index,
SAL salmeterol, SGRQ St George’s Respiratory Question-
naire, UMEC umeclidinium, VI vilanterol
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current smokers may show greater improve-
ments in lung function and larger reductions in
rescue medication use than former smokers; for
all other treatment groups and outcomes there
was overlap in the 95% CIs between subgroups.
Safety
A similar percentage of patients in each treat-
ment arm reported on-treatment AEs and SAEs,
and these percentages were similar in current
and former smokers (Table 3). There were no
drug-related SAEs in current or former smokers.
There were four fatal SAEs in each subgroup,
none of which were considered treatment-
related.
DISCUSSION
This prespecified analysis of the EMAX trial
suggests that both current and former smokers
experienced larger improvements in lung
Fig. 4 Proportion of responders for symptoms and health
status outcomes in A current smokers and B former
smokers. CAT COPD Assessment Test, CI confidence
interval, COPD chronic obstructive pulmonary disease,
E-RS Evaluating Respiratory Symptoms–COPD, SAC-
TDI self-administered computerized Transition Dyspnea
Index, SAL salmeterol, SGRQ St George’s Respiratory
Questionnaire, UMEC umeclidinium, VI vilanterol
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function and reductions in daily rescue medi-
cation use with UMEC/VI versus UMEC or SAL.
The study was not powered to investigate sub-
groups and care should be taken when inter-
preting the results. However, consistent
directional improvements with UMEC/VI versus
monotherapy were also observed for other
symptoms outcomes (SAC-TDI and E-RS). Fur-
thermore, patients receiving UMEC/VI also had
greater odds of improvements exceeding the
MCID for SAC-TDI and E-RS total score in cur-
rent and former smokers compared with UMEC
and SAL. A generally reduced risk of moder-
ate/severe exacerbations was observed with
UMEC/VI compared with monotherapy in both
subgroups, which is consistent with the find-
ings in the ITT population [21]. However,
longer studies are typically needed to fully
investigate treatment effect on exacerbations
and the EMAX trial included a relatively small
proportion of patients with a history of mod-
erate exacerbations in the past year (16% in the
ITT population). Former smokers also demon-
strated a reduced risk of a CID with UMEC/VI
Fig. 5 Change from baseline in A rescue medication inhalations/day and B percentage of rescue-free days across all time
points in current smokers. CI confidence interval, LS least squares, SAL salmeterol, UMEC umeclidinium, VI vilanterol
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versus both monotherapies, while current
smokers showed a consistent reduction in risk
versus SAL. All treatments demonstrated a sim-
ilar AE profile in both subgroups. Overall, these
findings are consistent with a treatment benefit
of dual bronchodilators compared with
monotherapy in patients with COPD who are
current or former smokers.
Current smokers demonstrated greater
improvements from baseline in lung function
with UMEC/VI and daily rescue medication use
on all treatments compared with former
smokers, with no overlap in the 95% CIs for the
two subgroups. This difference in treatment
outcomes may be related to baseline differences
between the subgroups; current smokers had a
more severe symptom burden than former
smokers, as demonstrated by higher baseline
E-RS, CAT, and SGRQ scores, although mean
baseline FEV1 was higher in current smokers.
The difference in baseline symptom severity
may be related to the smaller proportion of
current smokers receiving bronchodilator ther-
apy during run-in compared with former
Fig. 6 Change from baseline in A rescue medication inhalations/day and B percentage of rescue-free days across all time
points in former smokers. CI confidence interval, LS least squares, SAL salmeterol, UMEC umeclidinium, VI vilanterol
Adv Ther
smokers, since these undertreated patients may
be expected to show greater improvements
when initiating treatment at the start of the
trial.
On the basis of time-to-first-event analyses,
both current and former smokers generally
demonstrated a reduced risk of exacerbations
and disease worsening (CID) with UMEC/VI
versus UMEC or SAL. This treatment effect was
particularly prominent in former smokers, who
had a reduced risk of exacerbations and CID
across all definitions with UMEC/VI versus both
monotherapies. In contrast, current smokers
had consistently reduced risk with UMEC/VI
versus SAL, but only showed a benefit for one of
three CID definitions compared with UMEC,
and risk of a first exacerbation was similar
between the UMEC/VI and UMEC treatment
Fig. 7 Risk of a first CID in A current smokers and
B former smokers. an/N number of patients with an event/
number of patients with at least one post-baseline
assessment (not including exacerbations) for at least one
of the individual components or patients who had an
exacerbation; bmoderate/severe exacerbation. CAT COPD
Assessment Test, CI confidence interval, CID clinically
important deterioration, COPD chronic obstructive pul-
monary disease, FEV1 trough forced expiratory volume in
1 s, HR hazard ratio, SAC-TDI self-administered comput-
erized Transition Dyspnea Index, SAL salmeterol, SGRQ
St George’s Respiratory Questionnaire, UMEC umecli-
dinium, VI vilanterol
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Table 3 Adverse events














AE 163 (41) 163 (41) 160 (39) 152 (36) 153 (38) 154 (39)
Treatment-related AE 13 (3) 12 (3) 13 (3) 16 (4) 25 (6) 14 (4)
AE leading to study
withdrawal
15 (4) 17 (4) 13 (3) 17 (4) 20 (5) 13 (3)
SAE, n (%)
Nonfatal SAE 26 (7) 22 (6) 19 (5) 20 (5) 9 (2) 19 (5)
Treatment-related
nonfatal SAE
0 0 0 0 0 0
Fatal SAEa 3 (\ 1) 1 (\ 1) 0 1 (\ 1) 3 (\ 1) 0
Treatment-related fatal
SAE
0 0 0 0 0 0
Most frequent AEsb, n (%)
Nasopharyngitis 40 (10) 50 (13) 51 (12) 28 (7) 37 (9) 33 (8)
Upper respiratory tract
infection
8 (2) 5 (1) 9 (2) 11 (3) 7 (2) 11 (3)
Influenza 8 (2) 3 (\ 1) 7 (2) 12 (3) 6 (1) 11 (3)
Back pain 6 (2) 9 (2) 7 (2) 4 (\ 1) 4 (\ 1) 8 (2)
Cough 6 (2) 3 (\ 1) 4 (\ 1) 8 (2) 8 (2) 6 (2)
Bronchitis 5 (1) 2 (\ 1) 5 (1) 6 (1) 9 (2) 7 (2)
Headache 6 (2) 5 (1) 3 (\ 1) 4 (\ 1) 12 (3) 3 (\ 1)
COPD 5 (1) 4 (1) 2 (\ 1) 3 (\ 1) 6 (1) 8 (2)
Oropharyngeal pain 7 (2) 5 (1) 2 (\ 1) 1 (\ 1) 6 (1) 7 (2)
Hypertension 4 (1) 3 (\ 1) 4 (\ 1) 4 (\ 1) 9 (2) 1 (\ 1)
Sinusitis 7 (2) 3 (\ 1) 8 (2) 1 (\ 1) 4 (\ 1) 1 (\ 1)
Nausea 1 (\ 1) 6 (2) 3 (\ 1) 3 (\ 1) 5 (1) 3 (\ 1)
Dyspnea 0 3 (\ 1) 0 3 (\ 1) 7 (2) 6 (2)
Dizziness 4 (1) 6 (2) 2 (\ 1) 0 2 (\ 1) 1 (\ 1)
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arms in current smokers. However, the UMEC
arm showed the highest rates of early discon-
tinuation in the ITT population (UMEC/VI:
12%; UMEC: 19%; SAL: 16%) [21], which may
have biased the analysis of exacerbations in
favor of UMEC [26]. The small reduction in
exacerbations and CID risk for two definitions
with UMEC/VI versus UMEC in current smokers
may therefore be an anomaly related to the
excess early dropouts on the UMEC group, and
to the low proportion of patients with an
exacerbation in the prior year in the EMAX
population. In support of this, treatment dif-
ferences for the non-exacerbation components
of the CID composite (FEV1, SGRQ, CAT, and
SAC-TDI) were generally similar or larger in
current smokers than in former smokers. Previ-
ous studies have also shown similar effects of
LAMA monotherapy on lung function and
symptoms outcomes in current and former
smokers [18, 19, 27].
This analysis of EMAX provides longer-term
evidence of similar efficacy and safety of LAMA/
LABA therapy in current and former smokers,
consistent with the findings of a post hoc
analysis of the 12-week FLIGHT studies [20].
Taken together, the evidence suggests that dual-
bronchodilator therapy is a suitable mainte-
nance treatment option for both current and
former smokers with COPD. Nonetheless,
smoking cessation is an important aspect of the
management of COPD, and should be encour-
aged for all patients who smoke [4]. An impor-
tant aim of future studies will be to determine
whether dual-bronchodilator therapy can help
to minimize long-term risk and deterioration in
lung function; this is particularly pertinent in
former smokers, who have an elevated risk of
mortality and a greater rate of lung function
decline than nonsmokers [5, 6, 9].
A strength of this study is that EMAX selec-
ted an ICS-free population of patients with
COPD, allowing a prospective assessment of the
efficacy of dual and mono-bronchodilators
independent of the potentially confounding
effect of variable ICS use that has been noted in
previous trials [12, 28]. However, a major limi-
tation is that there were differences in patient
characteristics between current and former
smokers, which are consistent with a more
severe COPD symptom burden and less fre-
quent use of COPD maintenance therapy
among current smokers. These baseline differ-
ences limit the conclusions that can be drawn
regarding the effect of smoking status on long-
acting bronchodilator efficacy, although our
results do support greater efficacy of UMEC/VI
compared with UMEC or SAL in both sub-
groups. In addition, only approximately 16% of
the overall population had a history of exacer-
bations in the prior year, which together with
the 24-week duration of the study may have
limited the ability of the analysis to fully con-
firm reductions in exacerbation risk. Further-
more, the study was not powered to detect
treatment differences in the smoking status
subgroups.
Table 3 continued













Depression 2 (\ 1) 6 (2) 2 (\ 1) 0 0 2 (\ 1)
AE adverse event, COPD chronic obstructive pulmonary disease, SAE serious adverse event, SAL salmeterol, UMEC
umeclidinium, VI vilanterol
a A total of 8 fatal SAEs were reported, 4 each in the UMEC/VI (any cardiac disorder: n = 3, and pneumonia: n = 1) and
UMEC (any cardiac disorder: n = 1, and any respiratory, thoracic and mediastinal disorder: n = 3) treatment groups across
both smoking status subgroups; none were considered treatment-related by the investigators
b Includes all on-treatment AEs occurring in at least 2% of any treatment group
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CONCLUSION
In this analysis of the EMAX trial, dual-bron-
chodilator treatment with UMEC/VI provided
improvements in lung function and reduced
rescue medication use and was similarly well
tolerated compared with UMEC and SAL
monotherapy in both current and former
smokers. Directional improvements with
UMEC/VI versus monotherapy were observed in
both subgroups for other symptoms outcomes
(SAC-TDI and E-RS) and the risk of moder-
ate/severe exacerbations. Current smokers
showed greater overall benefits than former
smokers with all three treatments. These find-
ings suggest that dual-bronchodilator therapy is
a suitable treatment option for symptomatic
patients with COPD, regardless of their smoking
status.
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